DATASET RE-READ 2026-11-2042 PROGRAMSNEXLIFE PRICES READ 2026-11-20EVERY FIGURE CARRIES ITS READ DATE
TopGLP1Providers.comverified price index
DATED PRICES

NexLife vs ShedRx: November 2026 prices compared

As of November 20, 2026, from each program’s own page: on compounded tirzepatide, only NexLife prints a comparable month-to-month price, $129 a month; ShedRx shows only a starting-dose or coupon figure (from $239, "starting as low as"), so no like-for-like comparison is possible.

Released · Last reviewed · how we verify

On compounded semaglutide, only NexLife prints a comparable month-to-month price, $109 a month; ShedRx shows only a starting-dose or coupon figure (from $159, "GLP-1s from $159/mo" (drug not named)), so no like-for-like comparison is possible.

NexLife and ShedRx, measure by measure

NexLife and ShedRx side by side, from each program’s own page read November 20, 2026 (all-in: medication plus any required recurring fee, before tax)
MeasureNexLifeShedRx
Tirzepatide, month to month$129 (per month)from $239 (lowest printed: "starting as low as"; no month-to-month figure)
Tirzepatide, lowest printed$115 (12-month plan)$239 ("starting as low as")
Semaglutide, month to month$109 (per month)from $159 (lowest printed: "GLP-1s from $159/mo" (drug not named); no month-to-month figure)
Semaglutide, lowest printed$95 (12-month plan)$159 ("GLP-1s from $159/mo" (drug not named))
Dose pricingsame price at every dosepriced by dose or not stated
Membership or program feenonenone
Computed score33.6 of 40 (position 4 of 27)12 of 40 (position 16 of 27)
FDA warning letters730096 (2026-06-08)none listed
November 20 readfirst-party readfirst-party read

Strengths and limitations: which fits whom

NexLife prints one price at every dose with no membership, so a dose increase does not change the bill. ShedRx prints a month-to-month price; confirm whether it changes with the dose before you rely on it for a year. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.

What changed since August

The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.

What changed since the August 2026 capture (maintenance-dose all-in figure then; month-to-month all-in figure read November 20, 2026)
ProgramMedicationAugust 5–10, 2026November 20, 2026
ShedRxtirzepatide—from $239
ShedRxsemaglutide—from $159

Regulatory record

FDA’s warning-letter index lists warning letter 730096 (dated June 8, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to NexLife; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.

Check ShedRx’s current prices ↗

Frequently asked

Which is cheaper, NexLife or ShedRx?

On compounded tirzepatide, only NexLife prints a comparable month-to-month price, $129 a month; ShedRx shows only a starting-dose or coupon figure (from $239, "starting as low as"), so no like-for-like comparison is possible. On compounded semaglutide, only NexLife prints a comparable month-to-month price, $109 a month; ShedRx shows only a starting-dose or coupon figure (from $159, "GLP-1s from $159/mo" (drug not named)), so no like-for-like comparison is possible.

Do NexLife and ShedRx charge a membership fee?

NexLife: no membership fee; ShedRx: no membership fee. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.

Are NexLife and ShedRx medications FDA-approved?

Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.

NexLife recordNexLife alternativesShedRx recordShedRx alternativesAll head-to-headsRankingsPrice database

Sources

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.